Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuying Tan

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Cancer Letters|August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse modelJun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Letters|June 22, 2018
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Oncotarget|November 22, 2017
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Cancer Research|August 17, 2002
Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesisDavid Machover, Jacqueline Zittoun, Raphaël Saffroy, et al.
Cancer Research|September 18, 2004
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesZhijian Yang, Junhua Wang, Quan Lu, et al.
Oncotarget|February 9, 2018
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse modelsKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Anticancer Research|May 6, 2020
Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated LiposarcomaKentaro Igarashi, Kei Kawaguchi, Ming Zhao, et al.
Anticancer Research|September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of OsteosarcomaTakashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cell Cycle (Georgetown, Tex.)|December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and preventionKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Oncotarget|March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelsKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Cancer Letters|August 3, 2020
Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse modelJun Yamamoto, Kentaro Miyake, Qinghong Han, et al.
Cancer Letters|June 22, 2018
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancerKei Kawaguchi, Kentaro Miyake, Qinghong Han, et al.
Oncotarget|November 22, 2017
Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse modelKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Cancer Research|August 17, 2002
Treatment of cancer cells with methioninase produces DNA hypomethylation and increases DNA synthesisDavid Machover, Jacqueline Zittoun, Raphaël Saffroy, et al.
Cancer Research|September 18, 2004
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesZhijian Yang, Junhua Wang, Quan Lu, et al.
Oncotarget|February 9, 2018
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse modelsKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Anticancer Research|May 6, 2020
Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated LiposarcomaKentaro Igarashi, Kei Kawaguchi, Ming Zhao, et al.
Anticancer Research|September 15, 2019
Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatinum, Overcome Cisplatinum-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of OsteosarcomaTakashi Higuchi, Hiromichi Oshiro, Kentaro Miyake, et al.
Cell Cycle (Georgetown, Tex.)|December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and preventionKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Oncotarget|March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelsKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Pageof 10